Eagle Asset Management Inc. raised its position in Zoetis Inc (NYSE:ZTS) by 2.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 917,675 shares of the company’s stock after purchasing an additional 20,764 shares during the quarter. Eagle Asset Management Inc. owned 0.19% of Zoetis worth $114,333,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the business. Huntington National Bank raised its position in Zoetis by 3.0% in the second quarter. Huntington National Bank now owns 2,975 shares of the company’s stock valued at $338,000 after purchasing an additional 87 shares during the last quarter. Wilbanks Smith & Thomas Asset Management LLC raised its position in Zoetis by 1.8% in the second quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 4,980 shares of the company’s stock valued at $565,000 after purchasing an additional 89 shares during the last quarter. Vestmark Advisory Solutions Inc. raised its position in Zoetis by 0.6% in the second quarter. Vestmark Advisory Solutions Inc. now owns 15,106 shares of the company’s stock valued at $1,714,000 after purchasing an additional 89 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its position in shares of Zoetis by 1.4% during the third quarter. Municipal Employees Retirement System of Michigan now owns 6,720 shares of the company’s stock worth $837,000 after acquiring an additional 90 shares during the last quarter. Finally, Intellectus Partners LLC raised its position in shares of Zoetis by 1.1% during the second quarter. Intellectus Partners LLC now owns 8,040 shares of the company’s stock worth $912,000 after acquiring an additional 91 shares during the last quarter. Hedge funds and other institutional investors own 89.95% of the company’s stock.
In related news, EVP Clinton A. Jr. Lewis sold 6,123 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $128.62, for a total transaction of $787,540.26. Following the completion of the sale, the executive vice president now owns 39,141 shares of the company’s stock, valued at $5,034,315.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kristin C. Peck sold 11,500 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $123.22, for a total value of $1,417,030.00. Following the sale, the executive vice president now directly owns 48,877 shares of the company’s stock, valued at approximately $6,022,623.94. The disclosure for this sale can be found here. Insiders have sold 34,332 shares of company stock valued at $4,258,182 in the last ninety days. 0.29% of the stock is currently owned by insiders.
A number of brokerages have recently issued reports on ZTS. ValuEngine downgraded Zoetis from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Stifel Nicolaus set a $140.00 price objective on Zoetis and gave the stock a “buy” rating in a research report on Friday, September 13th. SunTrust Banks raised their price objective on Zoetis from $120.00 to $130.00 and gave the stock a “hold” rating in a research report on Tuesday, August 13th. Craig Hallum raised their price objective on Zoetis from $132.00 to $138.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, Barclays raised their price objective on Zoetis from $120.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $125.20.
NYSE ZTS traded down $3.17 during trading hours on Friday, hitting $117.86. 3,818,712 shares of the company’s stock were exchanged, compared to its average volume of 2,125,332. The stock has a 50-day simple moving average of $125.46 and a 200 day simple moving average of $116.48. Zoetis Inc has a 1-year low of $78.90 and a 1-year high of $130.20. The firm has a market cap of $57.43 billion, a price-to-earnings ratio of 37.65, a PEG ratio of 2.98 and a beta of 0.88. The company has a current ratio of 4.17, a quick ratio of 2.87 and a debt-to-equity ratio of 2.74.
Zoetis (NYSE:ZTS) last released its earnings results on Thursday, November 7th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.88 by $0.06. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The business had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.58 billion. During the same quarter last year, the firm posted $0.83 earnings per share. The firm’s revenue was up 7.0% on a year-over-year basis. On average, sell-side analysts anticipate that Zoetis Inc will post 3.57 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Tuesday, October 22nd will be paid a dividend of $0.164 per share. The ex-dividend date is Monday, October 21st. This represents a $0.66 annualized dividend and a yield of 0.56%. Zoetis’s dividend payout ratio is currently 21.09%.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
See Also: What is the QQQ ETF?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.